(PCRX) Pacira BioSciences - Ratings and Ratios

Pacira BioSciences, Inc. is a pharmaceutical company specializing in non-opioid pain management and regenerative health solutions, offering a range of products including EXPAREL, ZILRETTA, and iovera, which target postsurgical pain, osteoarthritis, and peripheral nerve pain. The companys product portfolio is designed to address the growing need for effective pain management alternatives to opioids.

The companys lead products, EXPAREL and ZILRETTA, have shown significant potential in managing pain and inflammation, with EXPAREL being used for postsurgical pain management and ZILRETTA for osteoarthritis knee pain. Additionally, the iovera system provides a non-opioid, handheld cryoanalgesia device for targeted pain relief. Paciras pipeline includes PCRX-201, a novel gene therapy platform that could potentially treat prevalent diseases like osteoarthritis.

From a technical analysis perspective, PCRXs stock price is currently at $24.34, below its 20-day and 50-day moving averages, indicating a potential short-term downtrend. However, the stock is above its 200-day moving average, suggesting a longer-term uptrend. The Average True Range (ATR) of 1.03 represents a 4.23% daily price movement, indicating moderate volatility.

Fundamentally, Pacira BioSciences has a market capitalization of $1.12 billion and a forward P/E ratio of 9.62, indicating a relatively reasonable valuation compared to its projected earnings. The companys return on equity (RoE) is currently negative, which may be a concern for investors. However, this could be attributed to the companys investment in research and development, including its gene therapy platform.

Based on the technical and fundamental data, a potential forecast for PCRX is that the stock may experience a short-term correction due to its current downtrend, but its long-term prospects remain positive due to its strong product portfolio and pipeline. If the company can successfully commercialize its gene therapy platform and continue to grow its revenue, its stock price could potentially reach $30-$35 in the next 12-18 months, representing a 23-43% upside from current levels.